The human folate receptor-alpha (FRα) was chosen as the target for clinical testing of IgE therapy because of its presence on the cell membrane (Fig. 2a) of a range of tumour types, and very limited expression on normal tissues18,19. This evidence concerns the gene FOLR1 and neoplasm.